Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy

Immune checkpoint blockade (ICB) therapies have revolutionized the treatment of human cancers including lung adenocarcinoma (LUAD). However, our understanding of the immune subtyping of LUAD and its association with clinical response of immune checkpoint inhibitor remains incomplete. Here we perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qinghua, Li, Meiling, Yang, Meng, Yang, Yichen, Song, Fengju, Zhang, Wei, Li, Xiangchun, Chen, Kexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066911/
https://www.ncbi.nlm.nih.gov/pubmed/32091408
http://dx.doi.org/10.18632/aging.102814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066911/
https://www.ncbi.nlm.nih.gov/pubmed/32091408
http://dx.doi.org/10.18632/aging.102814

Ejemplares similares